Zimmer Biomet Holdings Stock News

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poi

Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.

There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain

Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER in the fourth quarter.

Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $1.88 per share a year ago.

Zimmer Biomet Holdings Inc forecast 2024 profit above Wall Street expectations on Thursday, betting on resilient demand for its medical devices, and said it had initiated a restructuring program late

Zimmer Biomet: Weight Loss Drug Concerns Are Overblown

"Halftime Report" Investment Committee members Jason Snipe, Joe Terranova and Stephanie Link give their top picks to watch for the second half.

Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.